cellapy a repair- ceramide 3 lotion
gm holdings co., ltd - ceramide 3 (unii: 4370df050b) (ceramide 3 - unii:4370df050b) - ceramide 3 0.05 in 200 ml
glycerin & borax
psm healthcare ltd trading as api consumer brands - borax 12%; glycerol 88% - oral solution - 12 % - active: borax 12% glycerol 88%
palladia 10mg
zoetis australia pty ltd - toceranib - oral tablet - toceranib enzyme active 10.0 mg/tb - anti-neoplastic agent - dog | bitch | castrate | puppy - patnaik grade ii or iii recurrent | cutaneous mast cell tumours | node involvement in dogs | with or without regional lymph
palladia 15mg
zoetis australia pty ltd - toceranib - oral tablet - toceranib enzyme active 15.0 mg/tb - anti-neoplastic agent - dog | bitch | castrate | puppy - patnaik grade ii or iii recurrent | cutaneous mast cell tumours | node involvement in dogs | with or without regional lymph
palladia 50mg
zoetis australia pty ltd - toceranib - oral tablet - toceranib enzyme active 50.0 mg/tb - anti-neoplastic agent - dog | bitch | castrate | puppy - patnaik grade ii or iii recurrent | cutaneous mast cell tumours | node involvement in dogs | with or without regional lymph
eraxis anidulafungin 100 mg powder for injection vial
pfizer australia pty ltd - anidulafungin, quantity: 100 mg - injection, powder for - excipient ingredients: tartaric acid; mannitol; fructose; polysorbate 80 - treatment of invasive candidiasis, including candidaemia in adult and in paediatric patients one month and older (see section 5.1)
eraxis 100 mg
pfizer pfe pharmaceuticals israel ltd - anidulafungin - powder for concentrate for solution for infusion - anidulafungin 100 mg/vial - anidulafungin - anidulafungin - treatment of invasive candidiasis in adults and paediatric patients aged 1 month to < 18 years
glycerin of borax 12%w/v oral liquid ordinary liquids
sev pharmaceuticals limited; sev pharmaceuticals limited - glycerine+borax - oral liquid ordinary liquids - 12%w/v
elelyso
pfizer new zealand limited - taliglucerase alfa 200 u (200 u deliverable, plus 6% overage) - powder for injection - 200 u - active: taliglucerase alfa 200 u (200 u deliverable, plus 6% overage) excipient: citric acid mannitol polysorbate 80 sodium citrate dihydrate - elelyso is indicated for long-term enzyme replacement therapy for adult and paediatric patients with a confirmed diagnosis of type 1 gaucher disease associated with at least one of the following: splenomegaly, hepatomegaly, anaemia, thrombocytopenia.
palladia
zoetis belgium sa - toceranib - antineoplastic agents - dogs - treatment of non-resectable patnaik grade-ii (intermediate-grade) or -iii (high-grade), recurrent, cutaneous mast-cell tumours in dogs.